» Articles » PMID: 21548892

Use of a Negative Selectable Marker for Rapid Selection of Recombinant Vaccinia Virus

Overview
Journal Biotechniques
Date 2011 May 10
PMID 21548892
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinia virus has been a powerful tool in molecular biology and vaccine development. The relative ease of inserting and expressing foreign genes combined with its broad host range has made it an attractive antigen delivery system against many heterologous diseases. Many different approaches have been developed to isolate recombinant vaccinia virus generated from homologous recombination; however, most are time-consuming, often requiring a series of passages or specific cell lines. Herein we introduce a rapid method for isolating recombinants using the antibiotic coumermycin and the interferon-associated PKR pathway to select for vaccinia virus recombinants. This method uses a negative selection marker in the form of a fusion protein, GyrB-PKR, consisting of the coumermycin dimerization domain of Escherichia coli gyrase subunit B fused to the catalytic domain of human PKR. Coumermycin-dependent dimerization of this protein results in activation of PKR and the phosphorylation of translation initiation factor, eIF2α. Phosphorylation of this factor leads to an inhibition of protein synthesis, and an inhibition of virus replication. In the presence of coumermycin, recombinants are isolated due to the loss of this coumermycin-sensitive gene by homologous recombination. We demonstrate that this method of selection is highly efficient and requires limited rounds of enrichment to isolate recombinant virus.

Citing Articles

Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Wang Y Viruses. 2023; 15(8).

PMID: 37632084 PMC: 10457812. DOI: 10.3390/v15081742.


Efficient production of protein complexes in mammalian cells using a poxvirus vector.

Drillien R, Pradeau-Aubreton K, Batisse J, Mezher J, Schenckbecher E, Marguin J PLoS One. 2022; 17(12):e0279038.

PMID: 36520869 PMC: 9754296. DOI: 10.1371/journal.pone.0279038.


Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501Y Strain of SARS-CoV-2.

Kibler K, Szczerba M, Lake D, Roeder A, Rahman M, Hogue B Vaccines (Basel). 2022; 10(8).

PMID: 35893821 PMC: 9394475. DOI: 10.3390/vaccines10081172.


Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y strain of SARS-CoV-2.

Kibler K, Szczerba M, Lake D, Roeder A, Rahman M, Hogue B bioRxiv. 2021; .

PMID: 34909775 PMC: 8669842. DOI: 10.1101/2021.12.06.471483.


Development and Validation of an ELISA for the Detection of Bluetongue Virus Serotype 4-Specific Antibodies.

Breard E, Turpaud M, Beaud G, Postic L, Fablet A, Beer M Viruses. 2021; 13(9).

PMID: 34578322 PMC: 8473233. DOI: 10.3390/v13091741.


References
1.
Ali J, Jackson A, HOWELLS A, Maxwell A . The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry. 1993; 32(10):2717-24. DOI: 10.1021/bi00061a033. View

2.
Clemens M . PKR--a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol. 1997; 29(7):945-9. DOI: 10.1016/s1357-2725(96)00169-0. View

3.
Langland J, Jacobs B . Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. Virology. 2004; 324(2):419-29. DOI: 10.1016/j.virol.2004.03.012. View

4.
Jacobs B, Langland J, Brandt T . Characterization of viral double-stranded RNA-binding proteins. Methods. 1998; 15(3):225-32. DOI: 10.1006/meth.1998.0626. View

5.
Mackett M, Smith G, Moss B . General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984; 49(3):857-64. PMC: 255547. DOI: 10.1128/JVI.49.3.857-864.1984. View